Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Amoxicillin vs IV Ceftriaxone in Pediatric CAP
NCT06532409Not yet recruiting
- Sponsor
- RESnTEC (Research and Technology) Ltd
- Start
- Oct 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of amoxicillin in community acquired pneumonia (CAP) (2 arms), sponsored by RESnTEC (Research and Technology) Ltd. Primary endpoint: Free from fever at 3 days. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
amoxicillin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT06532409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532409.